RCS - ART MEDICAL - ART MEDICAL Announces Partnership With Teva Israel

General Motors CoAnnouncement

16/03/2023 16:15

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20230316:nRSP1286Ta&default-theme=true

RNS Number : 1286T  ART MEDICAL  16 March 2023

ART MEDICAL Announces Partnership With Teva Israel to Bring Its Lifesaving
Technology to Critical Care Units

ART MEDICAL Ltd. is pleased to announce its collaboration with Teva Israel.
Under the terms of the agreement, Teva Israel will market and distribute ART
MEDICAL's ground-breaking smART+ Platform in Israel's intensive care units.

NETANYA, ISRAEL / ACCESSWIRE / March 16, 2023 / The smART+ Platform
(https://pr.report/UCNWpXPJ) is a robotic-assisted technology that aims to
reduce complications related to feeding tube malposition, malnutrition
(https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6664107/#:~:text=A%20recent%20systematic%20review%20revealed%20the%20strikingly%20high%20prevalence%20of%20malnutrition%20in%20intensive%20care%20unit%20(ICU)%20patients%20(ranged%20from%2038%25%20to%2078%25)%2C)
, Ventilator-Associated Pneumonia (VAP)
(https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5710313/#:~:text=Its%20incidence%20ranges%20from%205%25%20to%2067%25%20depending%20on%20case%20mix%20and%20the%20diagnostic%20criteria%20used%2010%2C%20and%20the%20highest%20rates%20are%20in%20immunocompromised%2C%20surgical%2C%20and%20elderly%20patients.)
, and Acute Kidney Injury (AKI)
(https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4227114/#:~:text=The%20rates%20of%20incidence%20of%20AKI%20using%20the%20RIFLE%2C%20AKIN%2C%20and%20KDIGO%20criteria%20were%2046.9%25%2C%2038.4%25%2C%20and%2051%25%2C%20respectively.)
. By delivering transformative new-to-the-world data, the smART+ Platform
enables medical staff to take a comprehensive approach to critical care, make
informed decisions and improve patient outcomes.

Related Image
(https://cdn.newswire.com/files/x/e6/d4/6307cc2c635abf735992cda1ddb5.jpg)

 

Current related practices in intensive care units rely mostly on manual work
and cumbersome procedures. ICU patients are routinely subjected to the risks
of malnutrition, tube malposition, and pneumonia. Without technological
solutions, nutrition treatment leads to inaccuracies, increased workloads on
care teams, and generic nutrition plans that are neither personalized nor
updated in real time. The smART+ Platform uses a proprietary sensor-based
feeding tube, continuous metabolic assessment, and algorithms, to provide
real-time monitoring and closed-loop feedback, resulting in better and
personalized care for critically ill patients.

ART MEDICAL's Founder and CEO, Liron Elia, says, "Our goal, at ART MEDICAL, is
to improve patient outcomes through cutting-edge technology. By integrating
real-time data, monitoring, and control mechanisms, the smART+ Platform
addresses several of the greatest clinical challenges of intensive care units.
This powerful combination provides a comprehensive and innovative nutritional
therapy practice as well as optimized care delivery. We are thrilled to
partner with Teva Israel to bring our technology to critically ill patients
and clinical teams in ICUs."

Yossi Ofek, GM-Teva Israel, SVP; Cluster Head - Middle East, Africa &
Ukraine says:

"Teva Israel continually strives to offer innovative and safe treatment
options - both in the community and in hospitals - in order to improve the
lives and health of patients.

"The innovative development of an Israeli company, ART MEDICAL, is intended to
ensure that patients in intensive care units receive the most advanced
treatment offered today that can minimize complications related to
hospitalization and reduce length of stay."

About Teva Israel:

'Teva Israel' is the home-based marketing arm of Teva Pharmaceutical
Industries Ltd, where it has been working to improve the lives and health of
patients, for over 120 years, through high-quality and affordable medicines.

As a leading player in the local health market and particularly in the
generics and OTC markets, Teva Israel provides unique services in Israel to
Israeli residents, through its logistics company SLE - and markets a wide
variety of medicines and products: from original innovative medicines and
generic medicines, through medical equipment and devices for hospitals, to
over the counter (OTC) medicines and baby milk formula.

Teva Israel is also an innovation incubator for Teva Global and established,
in collaboration with Philips, Sanara Ventures, a platform for investments in
start-up companies in the fields of digital medicine and medical devices. In
Israel, one of every four prescriptions is for a Teva drug, while the annual
savings that the company's generic drugs bring to the Israeli healthcare
system is estimated at about one and a half billion shekels, per year.

About ART MEDICAL

ART MEDICAL is on a mission to save lives through technological innovations
and redefine the future of critical care. Our goal is to see ICU patients get
better faster with the help of real-time nutrition management. Visit
www.artmedical.com (https://pr.report/M1OFhXLW) or follow us on LinkedIn
(https://pr.report/wpWEi54Z) for more information.

Forward-Looking Statements of ART MEDICAL

ART MEDICAL developed the smART+™ Platform as a holistic approach for the
next-generation ICU, featuring an ecosystem of sensor-based tools, software,
and algorithms. smART+ is designed to prevent ICU-acquired complications. The
smART+ Platform aims to reduce length of ventilation days and length of stay
that are attributed to malnutrition, VAP, and other secondary infections and
complications, ultimately providing better care, and dramatically reducing
healthcare costs.

Disclaimer

THIS PRESS RELEASE AND ITS CONTENT IS NOT INTENDED AS AN OFFERING OR AS A
SOLICITATION TO AN OFFERING TO PURCHASE SECURITIES OF ANY OF THE
ABOVE-MENTIONED COMPANIES OR ANY OF THEIR AFFILIATES, DIRECTLY OR INDIRECTLY,
AND YOU MAY NOT RELY ON THIS PRESS RELEASE IN CONNECTION WITH AN INVESTMENT
DECISION.

Contact Information

Ori Braun

SVP Business Development
press@artmedical.com (mailto:press@artmedical.com)

SOURCE: ART MEDICAL

 

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

Reach is a non-regulatory news service. By using this service an issuer is confirming that the information contained within this announcement is of a non-regulatory nature. Reach announcements are identified with an orange label and the word “Reach” in the source column of the News Explorer pages of London Stock Exchange’s website so that they are distinguished from the RNS UK regulatory service. Other vendors subscribing for Reach press releases may use a different method to distinguish Reach announcements from UK regulatory news.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  NRAUVOBROKUOAAR